v3.25.2
Stockholders' Equity (Deficiency) - Series A Preferred Stock Securities Purchase Agreements (Details)
3 Months Ended 6 Months Ended
Jun. 20, 2025
USD ($)
$ / shares
shares
Jun. 30, 2025
$ / shares
shares
Jun. 30, 2025
USD ($)
$ / shares
shares
Jun. 17, 2025
shares
Dec. 31, 2024
$ / shares
shares
Stockholders' (Deficiency) Equity          
Net proceeds (in shares)   1,323,389 2,450,489    
Proceeds from sale of preferred stock and warrants in private placement | $     $ 50,000,000    
Preferred stock, par value | $ / shares   $ 0.0001 $ 0.0001   $ 0.0001
Preferred stock, shares authorized   6,000,000 6,000,000   6,000,000
Investor warrants          
Stockholders' (Deficiency) Equity          
Term of warrant 5 years        
Number of warrants issued 30,769,230        
Exercise price | $ / shares $ 3.25        
Placement agent warrants          
Stockholders' (Deficiency) Equity          
Term of warrant 5 years        
Number of warrants issued 1,846,153        
Exercise price | $ / shares $ 3.25        
Series A Preferred Stock          
Stockholders' (Deficiency) Equity          
Net proceeds (in shares) 5,128,205        
Shares Issued price per share | $ / shares $ 9.75        
Proceeds from sale of preferred stock and warrants in private placement | $ $ 50,000,000        
Preferred stock convertible ratio 0.33        
Preferred stock, par value | $ / shares $ 0.0001        
Preferred stock, shares authorized 5,435,898 5,435,898 5,435,898   5,435,898
Preferred stock convertible price | $ / shares $ 3.25        
Cumulative dividend rate 6.00%        
Liquidation preference | $ $ 50,097,167        
Issuance costs | $ 634,251        
Value of received securities | $ $ 3,000,000        
Compensation received for services 307,692        
Series A Preferred Stock | Investor warrants          
Stockholders' (Deficiency) Equity          
No. of common stock per warrant       6